Please wait...

Istodax (overfill)

Generic Name: romidepsin (ROE mi DEP sin)
Brand Names: Istodax
Istodax is used to treat T-cell lymphoma affecting the skin. Learn about side effects, interactions and indications.
  • Prescription Settings

Prices and coupons of Istodax (overfill)

Current Location: 20149 (Ashburn)
Change Location?

Enter your zip code

Please wait while the prices are loaded...

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Istodax (romidepsin) blocks certain enzymes in the body and interferes with the growth of tumor cells. Istodax is used to treat T-cell lymphoma affecting the skin (cutaneous T-cell lymphoma, or CTCL). It is usually given after other medicines have been tried without successful treatment of symptoms. Istodax may also be used for purposes not listed in this medication guide. Before you receive Istodax, tell your doctor if you have an electrolyte imbalance, a personal or family history of "Long QT syndrome," heart disease, kidney disease, or liver disease. Learn more

Istodax (overfill) Side Effects

Istodax Side Effects

Note: This document contains side effect information about romidepsin. Some of the dosage forms listed on this page may not apply to the brand name Istodax.

For the Consumer

Applies to romidepsin: intravenous powder for solution

Along with its needed effects, romidepsin (the active ingredient contained in Istodax) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking romidepsin:

More common

  • Abdominal or stomach cramps or pain
  • black, tarry stools
  • bleeding gums
  • blood in the urine or stools
  • blurred vision
  • bone pain
  • chest pain
  • chills
  • confusion
  • convulsions
  • cough or hoarseness
  • decreased urine output
  • difficulty with breathing
  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
  • drowsiness
  • dry mouth
  • fast or irregular heartbeat
  • fever
  • flushed, dry skin
  • fruit-like breath odor
  • headache
  • increased hunger
  • increased thirst
  • increased urination
  • joint pain, stiffness, or swelling
  • loss of appetite
  • lower back or side pain
  • muscle cramps in the hands, arms, feet, legs, or face
  • muscle spasms or twitching
  • nausea or vomiting
  • numbness or tingling in the hands, fingertips, feet, or lips
  • painful or difficult urination
  • pale skin
  • pinpoint red spots on the skin
  • seizures
  • sore throat
  • sores, ulcers, or white spots on the lips or in the mouth
  • sweating
  • swelling of the face, ankles, feet, lower legs, or hands
  • swollen glands
  • tremor
  • troubled breathing
  • unexplained weight loss
  • unusual bleeding or bruising
  • unusual tiredness or weakness

Some side effects of romidepsin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Change in taste
  • constipation
  • cracks in the skin
  • diarrhea
  • itching
  • lack or loss of strength
  • loss of appetite
  • loss of heat from the body
  • loss of taste
  • red, swollen skin
  • scaly skin
  • weight loss

For Healthcare Professionals

Applies to romidepsin: intravenous powder for injection


Very common (10% or more): Nausea (up to 86%), vomiting (up to 52%), constipation (up to 40%), diarrhea (up to 36%), abdominal pain (up to 14%)

Common (1% to 10%): Stomatitis


The most commonly reported adverse events included neutropenia, lymphopenia, thrombocytopenia, infections, nausea, fatigue, vomiting, anorexia, anemia, and ECG T-wave changes.

The most commonly reported events leading to discontinuation included infection, fatigue, dyspnea, QT prolongation, and hypomagnesemia.


Very common (10% or more): Anemia (up to 72%), neutropenia (up to 66%), leukopenia (up to 46%), thrombocytopenia (up to 65%), lymphopenia (up to 57%)


Very common (10% or more): ST-T wave changes on ECG (up to 63%); Hypotension (up to 23%)

Common (1% to 10%): Tachycardia, supraventricular arrhythmia, ventricular arrhythmia, edema, deep vein thrombosis, chest pain

Frequency not reported: QT prolongation


Very common (10% or more): Anorexia (up to 54%), hypocalcemia (up to 52%), hyperglycemia (up to 51%), hypoalbuminemia (up to 48%), hyperuricemia (up to 33%), hypomagnesemia (up to 28%), hypermagnesemia (up to 27%), hypophosphatemia (up to 27%), hypokalemia (up to 20%), weight loss (up to 15%), hyponatremia (up to 20%),

Common (1% to 10%): Dehydration, hypoalbuminemia, hyperuricemia, tumor lysis syndrome

Nervous system

Very common (10% or more): Dysgeusia (up to 40%), headache (up to 34%)

Common (1% to 10%): Syncope, dizziness


Very common (10% or more): AST elevations (up to 28%), ALT elevations (up to 22%)

Common (1% to 10%): Hyperbilirubinemia


Very common (10% or more): Pruritus (up to 31%), dermatitis/exfoliative dermatitis (up to 27%)

Common (1% to 10%): Rash


Common (1% to 10%): Hypersensitivity


Very common (10% or more): Infections (up to 54%)

Common (1% to 10%): Sepsis, upper respiratory infection, urinary tract infection, pneumonia, cellulitis, oral candidiasis, central line infection, catheter related infection


Very common (10% or more): Asthenia/fatigue (up to 77%), pyrexia (up to 47%), chills (up to 17%)

Common (1% to 10%): Febrile neutropenia


Very common (10% or more): Cough (up to 21%), dyspnea (up to 21%)

Common (1% to 10%): Pulmonary embolism, pneumonitis


Common (1% to 10%): Muscle spasms, myalgia

Editorial References and Review

Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.

Source: Drugs.com Istodax (overfill)